- Home
- YSG vs LXEO Comparison
YSG vs LXEO Comparison
Compare YSG & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSG
- LXEO
- Stock Information
- Founded
- YSG 2016
- LXEO 2017
- Country
- YSG China
- LXEO United States
- Employees
- YSG N/A
- LXEO 72
- Industry
- YSG Package Goods/Cosmetics
- LXEO
- Sector
- YSG Consumer Discretionary
- LXEO
- Exchange
- YSG Nasdaq
- LXEO Nasdaq
- Market Cap
- YSG 306.5M
- LXEO 190.9M
- IPO Year
- YSG 2020
- LXEO 2023
- Fundamental
- Price
- YSG $3.17
- LXEO $5.95
- Analyst Decision
- YSG
- LXEO Strong Buy
- Analyst Count
- YSG 0
- LXEO 5
- Target Price
- YSG N/A
- LXEO $23.80
- AVG Volume (30 Days)
- YSG 81.4K
- LXEO 219.1K
- Earning Date
- YSG 03-05-2025
- LXEO 02-11-2025
- Dividend Yield
- YSG N/A
- LXEO N/A
- EPS Growth
- YSG N/A
- LXEO N/A
- EPS
- YSG N/A
- LXEO N/A
- Revenue
- YSG $472,960,724.00
- LXEO N/A
- Revenue This Year
- YSG $2.29
- LXEO N/A
- Revenue Next Year
- YSG $5.70
- LXEO N/A
- P/E Ratio
- YSG N/A
- LXEO N/A
- Revenue Growth
- YSG N/A
- LXEO N/A
- 52 Week Low
- YSG $1.99
- LXEO $4.67
- 52 Week High
- YSG $5.22
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- YSG 37.70
- LXEO 43.99
- Support Level
- YSG $3.13
- LXEO $5.18
- Resistance Level
- YSG $3.31
- LXEO $5.60
- Average True Range (ATR)
- YSG 0.15
- LXEO 0.54
- MACD
- YSG 0.04
- LXEO 0.04
- Stochastic Oscillator
- YSG 24.53
- LXEO 51.01
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The Group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.